SiDMAP Founders to Provide Metabolomics Component of $5.6 Million Center Grant from the NIH to Study Mechanisms of Action in Both Inflammatory and Proliferative Diseases of the Pancreas

Share Article

SiDMAP, LLC, announced today that its co-founders, Drs. Paul Lee and Laszlo G. Boros, will provide the metabolic profiling component of the research conducted by the UCLA Center for Excellence in Pancreatic Disease, which recently received over $5.6 million from the NIH to study various disease mechanisms in the pancreas. The UCLA Center for Excellence in Pancreatic Disease is part of several grants recently received by UCLA investigators to study pancreatic related illnesses totaling $8,696,865.

We are extremely proud of Drs. Boros and Lee for their work in this area and for their recognition as investigators with the unique skills and experience in the area of metabolic profiling necessary to perform this important research

    "We are extremely proud of Drs. Boros and Lee for their work in this area and for their recognition as investigators with the unique skills and experience in the area of metabolic profiling necessary to perform this important research," said Ms. Agi Hirshberg, President and Founder of SiDMAP. "The multidisciplinary work to be performed by all the participating investigators who received funding from the NIH, will hopefully yield new insight into diseases of the pancreas and in particular, pancreatic cancer and the discovery of more effective treatments and reliable tools for earlier detection."

"We are excited to join this collaborative research effort and are pleased to be recognized by the NIH as the participating metabolomics solution provider for this important project," Dr. Lee commented.

The SiDMAP platform will be used by Drs. Lee and Boros to provide metabolic flux profiles in various models with the goal of understanding the phytonutrient mechanism of action in both inflammatory and proliferative diseases of the pancreas.

About SiDMAP

SiDMAP provides flux-based, metabolic profiling services to pharmaceutical, biotech and research organizations seeking to enhance their drug development processes, and develop further insights into a drug's mechanism of action and disease states. SiDMAP's unique tracer technology, exclusively licensed from Los Angeles BioMedical Research Institute at Harbor U.C.L.A Medical Center, measures metabolic pathway flux to gain unique insights into cell function. A SiDMAP assay provides clients with an accurate, dynamic metabolic analysis of a compound's biological impact in both in vitro and in vivo systems and in humans for the development of clinical and pre-clinical biomarkers. SiDMAP is headquartered in Los Angeles, California.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Manheim
SiDMAP, LLC
310-478-1424 x303
Email >